Key Points
- Labcorp EVP Amy Summy sold 924 shares at an average price of $306.74, generating $283,427.76; her remaining stake fell 11.73% to 6,956 shares.
- Labcorp reported quarterly EPS of $4.99, beating estimates of $4.78, while revenue rose 5.8% year over year to $3.73 billion. The company set fiscal 2026 EPS guidance at $18.10–$18.55.
- Analysts maintain a generally positive view, with nine Buy ratings and three Holds, producing a “Moderate Buy” consensus and an average price target of $326.82. Labcorp also declared a quarterly dividend of $0.72 per share.
Labcorp Holdings Inc. (NYSE:LH - Get Free Report) EVP Amy Summy sold 924 shares of the business's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total transaction of $283,427.76. Following the transaction, the executive vice president owned 6,956 shares in the company, valued at approximately $2,133,683.44. This represents a 11.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Labcorp Trading Up 0.9%
NYSE LH opened at $316.93 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. Labcorp Holdings Inc. has a 1-year low of $244.52 and a 1-year high of $317.10. The firm's fifty day simple moving average is $278.94 and its 200-day simple moving average is $272.54. The company has a market capitalization of $25.99 billion, a PE ratio of 26.21, a price-to-earnings-growth ratio of 1.81 and a beta of 0.87.
Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The firm had revenue of $3.73 billion during the quarter, compared to analysts' expectations of $3.71 billion. During the same quarter last year, the firm earned $4.35 earnings per share. The business's revenue for the quarter was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. As a group, sell-side analysts anticipate that Labcorp Holdings Inc. will post 18.35 earnings per share for the current fiscal year.
Labcorp Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, August 28th. Labcorp's payout ratio is currently 23.82%.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. REAP Financial Group LLC increased its holdings in Labcorp by 20.4% in the 4th quarter. REAP Financial Group LLC now owns 218 shares of the medical research company's stock valued at $55,000 after acquiring an additional 37 shares during the last quarter. V Square Quantitative Management LLC boosted its holdings in shares of Labcorp by 1.7% in the 1st quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company's stock worth $645,000 after purchasing an additional 40 shares during the period. Hilltop Holdings Inc. increased its position in Labcorp by 2.6% during the fourth quarter. Hilltop Holdings Inc. now owns 1,631 shares of the medical research company's stock valued at $409,000 after acquiring an additional 41 shares during the last quarter. Larson Financial Group LLC raised its position in Labcorp by 37.5% in the 3rd quarter. Larson Financial Group LLC now owns 154 shares of the medical research company's stock worth $44,000 after purchasing an additional 42 shares during the period. Finally, Pinnacle Associates Ltd. raised its position in Labcorp by 3.9% in the 4th quarter. Pinnacle Associates Ltd. now owns 1,126 shares of the medical research company's stock worth $282,000 after purchasing an additional 42 shares during the period. 95.94% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several brokerages recently weighed in on LH. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $306.00 price objective on shares of Labcorp in a research report on Friday, July 31st. Truist Financial boosted their target price on shares of Labcorp from $320.00 to $350.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. Bank of America increased their price target on shares of Labcorp from $300.00 to $320.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Robert W. Baird set a $352.00 price objective on shares of Labcorp in a research note on Friday, July 31st. Finally, Morgan Stanley upped their price objective on shares of Labcorp from $308.00 to $338.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $326.82.
Check Out Our Latest Stock Report on LH
About Labcorp
(
Get Free Report)
Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.
Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
